H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Eton Pharmaceuticals (ETON) today and set a price target of $18.00. The company’s shares closed last Friday at $4.78.
According to TipRanks.com, Selvaraju is a top 100 analyst with an average return of 28.5% and a 59.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Black Diamond Therapeutics, and Biospecifics Technologies.
Eton Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $14.00, implying a 191.7% upside from current levels. In a report issued on May 15, B.Riley FBR also reiterated a Buy rating on the stock with a $10.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.07 and a one-year low of $2.50. Currently, Eton Pharmaceuticals has an average volume of 79.01K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines. The company was founded in April 2017 and is headquartered in Deer Park, IL.
